NCT03437720View on ClinicalTrials.gov

Assessment of the Safety and Effect of SAR425899 Versus Placebo for the Treatment of Non-alcoholic Fatty Liver Disease

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 23, 2019

Primary Completion Date

August 25, 2021

Study Completion Date

August 25, 2021

Conditions
Non-alcoholic SteatohepatitisType 2 Diabetes Mellitus
Interventions
DRUG

SAR425899

"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection"

DRUG

Placebo

"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection"

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT03437720 - Assessment of the Safety and Effect of SAR425899 Versus Placebo for the Treatment of Non-alcoholic Fatty Liver Disease | Biotech Hunter | Biotech Hunter